Zai Lab (HKG:9688) Stock Price & Overview

Zai Lab Limited (HKG:9688)

Hong Kong · Delayed Price · Currency is HKD

28.45

+1.35 (4.98%)

Jun 5, 2025, 3:45 PM HKT

85.46% (1Y)

Market Cap	30.71B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.96B
Shares Out	n/a
EPS (ttm)	-19.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,762,130
Average Volume	11,688,694
Open	28.00
Previous Close	27.10
Day's Range	27.95 - 29.65
52-Week Range	12.32 - 32.50
Beta	1.04
RSI	66.19
Earnings Date	May 8, 2025

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 1,869

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 9688

Full Company Profile

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD Financial Statements

News

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab Limited (NASDAQ: ZLAB) and NovoCure Limited (NASDAQ: NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic can...

2 days ago - Benzinga

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating z...

3 days ago - Business Wire

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor...

4 days ago - Business Wire

Zai Lab Announces Participation in Investor Conferences in June 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

6 days ago - Business Wire

Zai Lab Limited Is Well Positioned For Long-Term Growth

8 days ago - Seeking Alpha

Zai Lab Limited: Banking On Chinese Pharma Growth

13 days ago - Seeking Alpha

Zai Lab gets FDA fast track status for lung cancer treatment

Zai Lab's ZL-1310 receives FDA fast-track & orphan drug status for small cell lung cancer. Read more here.

16 days ago - Seeking Alpha

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the ...

17 days ago - Business Wire

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

24 days ago - Seeking Alpha

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corpo...

4 weeks ago - Business Wire

Earnings Scheduled For May 8, 2025

Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...

4 weeks ago - Benzinga

Zai Lab Q1 2025 Earnings Preview

4 weeks ago - Seeking Alpha

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational...

5 weeks ago - Business Wire

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Ltd (NASDAQ: NVCR) reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents . Sales increased 12% year over year...

5 weeks ago - Benzinga

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

6 weeks ago - Business Wire

Zai Lab gets China's acceptance for label expansion of repotrectinib

6 weeks ago - Seeking Alpha

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New ...